Navigation Links
Novel anti-malarial drug candidate found by UT Southwestern researchers
Date:5/25/2010

DALLAS May 25, 2010 As part of a multicenter study, UT Southwestern Medical Center researchers have identified a series of chemical compounds that might serve as starting points for the identification of new classes of anti-malarial drugs.

"Malaria remains one of the most globally significant infectious diseases that we face," said Dr. Margaret Phillips, professor of pharmacology at UT Southwestern and one of the senior authors of the study, which appears in the May 20 issue of Nature. Malaria affects about 40 percent of the world's population and kills about a million people a year, she said. The parasite that causes the disease is spread by mosquito bites.

Drugs are the mainstay of malaria treatment, yet the malaria parasite is notorious for developing drug resistance, which compromises current chemotherapy.

"Novel chemical compounds with anti-malarial activity represent a potent tool in the process of developing new drugs to treat this disease," Dr. Phillips said.

The study, done in collaboration with Dr. Kiplin Guy of St. Jude Children's Research Hospital in Memphis and other researchers, started with a "library" of 309,474 chemical compounds.

The researchers used a technique called high throughput screening, which allowed them to test thousands of compounds quickly to identify those with anti-malarial action.

"In addition, publishing the full set of identified compounds will maximize the chances for the most-promising candidates to move into large-scale drug development programs," Dr. Phillips said.

The screen identified 1,152 compounds that killed the parasite. The researchers then followed up with further tests to determine the mechanism of action of the identified compounds, where possible.

Dr. Phillips and her group tested whether any of the identified compounds killed malaria parasites by inhibiting an enzyme necessary to make pyrimidine, an intermediate molecule for creating DNA. She discovered that three of the library's compounds with anti-malarial activity blocked this enzyme. Two of those had similar chemical structures to a class of known compounds that she and her colleagues have been studying for possible drug development. The third compound previously was not known to target the enzyme.

"It looked very different from anything we knew about before," she said.

Having a variety of anti-malarial drugs with different chemical structures and modes of action is important because different types of drugs are given together to slow the parasite from developing resistance, Dr. Phillips said.

In all, the researchers from the various centers found 172 compounds that are "reasonable starting points" for development of new types of drugs.

"We call the identified candidates 'hits,' but if any of them are going to become drugs, they're going to have to undergo chemical modification," Dr. Phillips said. "For instance, they may need to be altered chemically to enter the cell more easily, or to improve their pharmacology so they will be more effective in people."


'/>"/>

Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
2. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
3. Third European Novel Food Approval Received by Tahitian Noni International
4. Novel nanoparticles prevent radiation damage
5. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
6. Novel Method Eyed for Normalizing Blood Sugar
7. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
8. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
9. Novel medical home program for pediatric patients, families cuts ER visits in half
10. Novel stroke treatment passes safety stage of UCI-led clinical trial
11. Reovirus may be a novel approach to prostate cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology: